LEADER 00849nam0-22003371i-450- 001 990002071340403321 005 20021010 035 $a000207134 035 $aFED01000207134 035 $a(Aleph)000207134FED01 035 $a000207134 100 $a20021010d--------km-y0itay50------ba 101 0 $aita 200 1 $aGalapagos world ' s end$fWilliam Beebe 210 $aNew York$cG.P. Putnam ' s Sons$d1924 215 $a443 p.$d24 cm 610 0 $aFauna 610 0 $aUccelli 610 0 $aTartarughe 610 0 $aRettili 610 0 $aPesci 676 $a591 700 1$aBeebe,$bWilliam$f<1877-1962>$084644 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990002071340403321 952 $a61 XI 6/45$b694$fDAGEN 959 $aDAGEN 996 $aGalapagos world ' s end$9394062 997 $aUNINA DB $aING01 LEADER 00937nam0-22003131i-450- 001 990002900350403321 010 $a0-89871-416-8 035 $a000290035 035 $aFED01000290035 035 $a(Aleph)000290035FED01 035 $a000290035 100 $a20000920d1998----km-y0itay50------ba 101 0 $aENG 200 1 $aWavelets and their applications$ecase studies$fedited by Mei Kobayashi 210 $aPhiladelphia$cSiam$d1998 215 $axvi, 142 p.$d24 cm 610 0 $aAnalisi multivariata e multidimensionale dei dati 610 0 $aApplicazioni dell'analisi multivariata dei dati 676 $a515.2433 700 1$aWavelets And their Applications$0493796 702 1$aKobayashi,$bMei 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990002900350403321 952 $aXI-C-12$b6935$fMAS 959 $aMAS 996 $aWavelets and their applications$9466609 997 $aUNINA DB $aING01 LEADER 04390nam 2200649Ia 450 001 9910785015103321 005 20230725024654.0 010 $a0-309-15368-9 010 $a1-282-64481-5 010 $a9786612644818 010 $a0-309-14629-1 035 $a(CKB)2670000000040029 035 $a(EBL)3378619 035 $a(SSID)ssj0000419516 035 $a(PQKBManifestationID)11327351 035 $a(PQKBTitleCode)TC0000419516 035 $a(PQKBWorkID)10383882 035 $a(PQKB)11533418 035 $a(Au-PeEL)EBL3378619 035 $a(CaPaEBR)ebr10395833 035 $a(CaONFJC)MIL264481 035 $a(OCoLC)648761504 035 $a(MiAaPQ)EBC3378619 035 $a(EXLCZ)992670000000040029 100 $a20100125d2010 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aHepatitis and liver cancer$b[electronic resource] $ea national strategy for prevention and control of hepatitis B and C /$fHeather M. Colvin and Abigail E. Mitchell, editors; Committee on the Prevention and Control of Viral Hepatitis Infections, Board on Population Health and Public Health Practice 210 $aWashington, DC $cNational Academies Press$dc2010 215 $a1 online resource (253 p.) 300 $aDescription based upon print version of record. 311 $a0-309-14628-3 320 $aIncludes bibliographical references and index. 327 $a""Front Matter""; ""Reviewers""; ""Acknowledgments""; ""Contents""; ""Acronyms and Abbreviations""; ""Summary""; ""1 Introduction""; ""2 Surveillance""; ""3 Knowledge and Awareness About Chronic Hepatitis B and Hepatitis C""; ""4 Immunization""; ""5 Viral Hepatitis Services""; ""Appendix A: Committee Biographies""; ""Appendix B: Public Meeting Agendas""; ""Index"" 330 $a"The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations."--Publisher's description. 606 $aHepatitis B$zUnited States 606 $aHepatitis C$zUnited States 606 $aLiver$xCancer$zUnited States 615 0$aHepatitis B 615 0$aHepatitis C 615 0$aLiver$xCancer 676 $a616.99/436 701 $aColvin$b Heather M$01474463 701 $aMitchell$b Abigail E$01474464 712 02$aInstitute of Medicine (U.S.).$bCommittee on the Prevention and Control of Viral Hepatitis Infections. 712 02$aInstitute of Medicine (U.S.).$bBoard on Population Health and Public Health Practice. 712 02$aNational Academies Press (U.S.) 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910785015103321 996 $aHepatitis and liver cancer$93688198 997 $aUNINA